NICE Cites Cost in Deciding Against Atezolizumab for Frontline Advanced Small Cell Lung Cancer

January 6, 2020 – The United Kingdom’s National Institute for Health and Care Excellence (NICE) did not recommend granting marketing authorization to atezolizumab in combination with carboplatin and etoposide for the treatment of patients with treatment-naïve extensive-stage small cell lung cancer (ES-SCLC). In its appraisal consultation document, the agency explained that while the combination is suggested to improve overall survival (OS), patients in the National Health … (leggi tutto)